Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Rompen, Eric ; Université de Liège - ULiège > Département de science dentaire > Chirurgie bucco-dentaire et parodontologie
Boutsen, Y.
Body, J. J.
Bergmann, P.
Rozenberg, S.
GASPARD, Ulysse ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique
Reychler, H.
Language :
English
Title :
L'ostéonécrose maxillaire associée aux traitements aux bisphosphonates dans le traitement de l'ostéoporose. Consensus interdisciplinaire
Publication date :
2010
Journal title :
Louvain Medical
ISSN :
0024-6956
Publisher :
Université Catholique de Louvain. Faculté de Médecine, Louvain, Belgium
Lyles KW, Colon-Emeric CS, Magaziner JS et al. : Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357 : 1799-1809.
Boonen S, Body J-J, Boutsen Y, Devogelaer J-P, Goemaere S, Kaufman J-M, Rozenberg S, Reginster J-Y : Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int. 2005; 16 : 239-254.
Marx RE : Uncovering the cause of "Phossy Jaw" circa 1858 to 1906: Oral and maxillofacial surgery closed case files - case closed. J Oral Maxillofac Surg. 2008; 66 : 2356-2363.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Methrotra B : American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonatase-Related Osteonecrosis of the Jaws - 2009 update. J Oral Maxillofac Surg. 2009; 67 (suppl 1) : 2-12.
Bilezikian JP : Osteonecrosis of the jaw - do bisphosphonates pose a risk ? N Engl J Med. 2006; 355 : 2278-2281.
Black DM, Delmas PD, Eastell R et al. : Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356 : 1809-1822.
Favia G, Pilolli GP, Maiorano E : Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol. 2009; 36 : 2780-2787.
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23 : 8580-8587.
Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L et al.: Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol. 2006; 17 : 1512-1516.
Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M et al.: Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer. 2009; 7 : 3 (suppl): 2-3 (2 Late breaking abstract).
Schwartz HC : Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg. 1982; 4 : 251-253.
Marx RE, Cillo JE, Ulloa JJ : Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofacial Surg. 2007; 65 : 2397-2410.
Kwon Y-D, Kim D-Y, Ohe J-Y, Yoo J-Y, Walter C : Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67 : 2644-2648.
Gallagher AM, Rietbrock S, Olson M, van Staa TP : Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008; 23 : 1569-1575.
Baim S, Miller PD : Perspective. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009; 24 : 561-574.
Lesclous P, Najm SA, Carrel J-P et al.: Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation 7 Bone. 2009; 45 : 834-852.
Reid IR, Bolland MJ, Grey AB : Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity ? Bone. 2007; 41 : 318-320.
Lane N, Armitage GC, Loomer P et al.: Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005; 76 : 1113-1122.
Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM : The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005; 87 : 2155-2159.
Khosla S, Burr D, Cauley J et al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task-force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22 : 1479-1491.
Rizzoli R, Burlet N, Cahall D et al.: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008; 42 : 841-847.
Madrid C, Sanz M : What impact do systemically administrated bisphosphonates have on oral implant therapy ? A systematic review. Clin Oral Implants Res. 2009; 20 (suppl 4) : 87-95.
Grant BT, Amendo C, Freeman K, Kraut RA : Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. 2008; 66 : 223-230.
